Roche’s Foundation Medicine rebranded Saga Diagnostics’ minimal residual disease test after the $595 million acquisition earlier this year, positioning the assay for new indications beyond breast cancer. The test now called FoundationOne MRD uses tumor-informed selection of structural variants from whole-genome sequencing, followed by digital PCR on circulating tumor DNA, with an approximately 48-hour turnaround. The company emphasized the choice of structural variants to improve sensitivity and specificity, including reduced false calls linked to sequencing errors seen in point-mutation-only approaches. Foundation Medicine also argued structural variants are more stable over time than point mutations as disease evolves. Roche described the test as flexible for use at any laboratory by pairing its workflow with compatible digital PCR systems, including its Digital Lightcycler. The rebrand signals an effort to expand MRD testing footprints while leveraging the molecular approach that helped drive the Saga deal.